Ifrah Financial Services Inc. cut its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 7.2% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,687 shares of the company’s stock after selling 287 shares during the period. Ifrah Financial Services Inc.’s holdings in Johnson & Johnson were worth $572,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also modified their holdings of the company. GW&K Investment Management LLC purchased a new position in Johnson & Johnson in the fourth quarter valued at approximately $35,000. Dark Forest Capital Management LP boosted its holdings in shares of Johnson & Johnson by 1,044.4% in the 4th quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock valued at $36,000 after buying an additional 188 shares in the last quarter. Ruedi Wealth Management Inc. acquired a new stake in Johnson & Johnson during the 4th quarter worth $42,000. Kepos Capital LP purchased a new stake in Johnson & Johnson in the fourth quarter valued at $45,000. Finally, VitalStone Financial LLC acquired a new position in Johnson & Johnson in the fourth quarter valued at $52,000. 67.57% of the stock is currently owned by institutional investors and hedge funds.
Insider Transactions at Johnson & Johnson
In related news, EVP Kathryn E. Wengel sold 12,465 shares of Johnson & Johnson stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the completion of the sale, the executive vice president now owns 65,934 shares in the company, valued at approximately $10,549,440. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, VP Peter Fasolo sold 20,000 shares of the stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the transaction, the vice president now directly owns 102,696 shares in the company, valued at approximately $17,491,182.72. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Kathryn E. Wengel sold 12,465 shares of the business’s stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the completion of the sale, the executive vice president now owns 65,934 shares of the company’s stock, valued at $10,549,440. The disclosure for this sale can be found here. Insiders sold a total of 47,163 shares of company stock valued at $7,928,856 in the last ninety days. Corporate insiders own 0.20% of the company’s stock.
Analyst Upgrades and Downgrades
Read Our Latest Research Report on JNJ
Johnson & Johnson Stock Down 0.1 %
Shares of NYSE JNJ opened at $173.07 on Thursday. The company has a quick ratio of 0.88, a current ratio of 1.12 and a debt-to-equity ratio of 0.44. The firm has a 50-day moving average price of $164.21 and a 200 day moving average price of $161.13. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $181.04. The stock has a market capitalization of $449.80 billion, a price-to-earnings ratio of 35.03, a price-to-earnings-growth ratio of 2.90 and a beta of 0.54.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings results on Thursday, July 20th. The company reported $2.80 EPS for the quarter, topping the consensus estimate of $2.62 by $0.18. The business had revenue of $25.53 billion for the quarter, compared to analyst estimates of $24.63 billion. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The company’s quarterly revenue was up 6.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.59 EPS. Equities research analysts anticipate that Johnson & Johnson will post 10.75 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Stockholders of record on Monday, August 28th will be given a $1.19 dividend. The ex-dividend date of this dividend is Friday, August 25th. This represents a $4.76 annualized dividend and a dividend yield of 2.75%. Johnson & Johnson’s dividend payout ratio is presently 96.36%.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Read More
- Five stocks we like better than Johnson & Johnson
- Insider Trading – What You Need to Know
- 3 Stocks to Buy No Matter Which Way Inflation Moves
- What Are Dividend Champions? How to Invest in the Champions
- 7 Best Fintech ETFs to Buy Now
- How to Calculate Return on Investment (ROI)
- 2 Alternatives To Tesla (1 Safe, 1 More Risky)
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
